OncoMatch/Clinical Trials/NCT06980480
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Is NCT06980480 recruiting? Yes, currently enrolling (Sep 2026). This Phase 3 trial studies IGI, 10% for multiple myeloma.
Treatment: IGI, 10% — Multiple myeloma is a cancer of the plasma cells in the bone marrow. The main aim of this study is to learn how well the Immune Globulin Infusion (human), 10 percentage (%) (IGI, 10%) can help prevent infections in participants with multiple myeloma receiving B-cell maturation antigen (BCMA) x cluster of differentiation 3 (CD3) directed bispecific antibody therapy. Participants will be randomly assigned to one of two groups: 1. Primary infection prevention group: They will receive IGI, 10% for 12 months. 2. Secondary infection prevention group: They will only receive IGI, 10% if they develop a serious infection during the 12 months study period. During the study, participants will visit their study clinic 15 times (for 4-week dosing interval) or 19 times (for 3-week dosing interval) and their total participation duration will be up to 14 months (including screening period approximately 8 weeks).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: B-cell maturation antigen x CD3-directed bispecific antibody therapy (teclistamab)
Participant who recently started teclistamab monotherapy within the first 8 weeks of their planned treatment schedule and are planned to receive teclistamab for the next 12 months
Cannot have received: other B-cell maturation antigen x CD3-directed bispecific antibody therapy
received other B Cell Maturation Antigen (BCMA)*Cluster of Differentiation (CD3)-directed Bispecific Antibody therapy (BsAb), BCMA-targeted chimeric antigen receptor T-cell (CAR T-cell), or BCMA-targeted antibody drug conjugate (ADC) therapy within 1 year prior to screening
Cannot have received: BCMA-targeted chimeric antigen receptor T-cell therapy
received other B Cell Maturation Antigen (BCMA)*Cluster of Differentiation (CD3)-directed Bispecific Antibody therapy (BsAb), BCMA-targeted chimeric antigen receptor T-cell (CAR T-cell), or BCMA-targeted antibody drug conjugate (ADC) therapy within 1 year prior to screening
Cannot have received: BCMA-targeted antibody drug conjugate therapy
received other B Cell Maturation Antigen (BCMA)*Cluster of Differentiation (CD3)-directed Bispecific Antibody therapy (BsAb), BCMA-targeted chimeric antigen receptor T-cell (CAR T-cell), or BCMA-targeted antibody drug conjugate (ADC) therapy within 1 year prior to screening
Lab requirements
Kidney function
estimated glomerular filtration rate <30 mL/min/1.73 m^2
moderate to severe renal dysfunction based on an estimated glomerular filtration rate less than (<) 30 milliliters per minute per 1.73 square meters (mL/min/1.73 m^2)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Infirmary Health - Diagnostic & Medical Clinic (DMC) · Mobile, Alabama
- Chao Family Comprehensive Cancer Center UCI · Orange, California
- University of Kansas · Westwood, Kansas
- University of Maryland | Greenebaum Cancer Center · Baltimore, Maryland
- Henry Ford Health System · Detroit, Michigan
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06980480 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior other B-cell maturation antigen x CD3-directed bispecific antibody therapy, BCMA-targeted chimeric antigen receptor T-cell therapy, BCMA-targeted antibody drug conjugate therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages